Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021 (English version)

Zhu, Jun; Ma, Jun; CSCO, Union for China Lymphoma Investigators of

doi:10.21147/j.issn.1000-9604.2021.03.01

Cited by 38 publications

(34 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PTCL accounts for 25%−30% of all non-Hodgkin’s lymphoma (NHL) cases in China, which is higher than that in America and Europe (10%−15%) ( 1 - 4 ). Frontline therapies usually include cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or CHOP-like regimens ( 3 , 4 ). However, efficacy results from anthracycline-containing regimens are not satisfactory, with low complete response rates (CRR) and poor progression-free survival (PFS) and overall survival (OS) ( 5 ), underscoring the high unmet medical need.…”

Section: Introductionmentioning

confidence: 99%

Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma

Gui¹,

Cao²,

Ji³

et al. 2021

Chinese Journal of Cancer Research

Self Cite

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma

Gui¹,

Cao²,

Ji³

et al. 2021

Chinese Journal of Cancer Research

Self Cite

View full text Add to dashboard Cite

“…We also found that some metabolic genes such as ADH1B , PHGDH , BCAT2 , ME3 , PCCB , and CS were positively correlated with PD-1. PD-1 inhibitors such as pembrolizumab have been used as a third-line drug for the treatment of GC, revealing the important role of immunotherapy in GC ( Zhu and Ma, 2021 ). Research has shown that the combined use of PD-1 with small molecule drugs targeting metabolic pathways including amino acid metabolism may contribute to the effectiveness of PD-1 therapy.…”

Section: Discussionmentioning

confidence: 99%

Identification of 14 Differentially-Expressed Metabolism-Related Genes as Potential Targets of Gastric Cancer by Integrated Proteomics and Transcriptomics

Zhang

Liu²,

Wei³

et al. 2022

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Although research on the metabolism related to gastric cancer (GC) is gradually gaining increasing interest, there are few studies regarding metabolism-related genes in GC. Understanding the characteristic changes of metabolism-related genes at the transcriptional and protein levels in GC will help us to identify new biomarkers and novel therapeutic targets. We harvested six pairs of samples from GC patients and evaluated the differentially expressed proteins using mass spectrometry-based proteomics. RNA sequencing was conducted simultaneously to detect the corresponding expression of mRNAs, and bioinformatics analysis was used to reveal the correlation of significant differentially expressed genes. A total of 57 genes were observed to be dysregulated both in proteomics and transcriptomics. Bioinformatics analysis showed that these differentially expressed genes were significantly associated with regulating metabolic activity. Further, 14 metabolic genes were identified as potential targets for GC patients and were related to immune cell infiltration. Moreover, we found that dysregulation of branched-chain amino acid transaminase 2 (BCAT2), one of the 14 differentially expressed metabolism-related genes, was associated with the overall survival time in GC patients. We believe that this study provides comprehensive information to better understand the mechanism underlying the progression of GC metastasis and explores the potential therapeutic and prognostic metabolism-related targets for GC.

show abstract

“…Non-Hodgkin lymphoma (NHL) is a common type of cancer around the world, accounting for about 2.8% of new cancer cases and 2.6% of cancer deaths in 2018 ( 1 ). Diffuse large B cell lymphoma (DLBCL) is the most common subtype of NHL ( 2 ). Approximately two thirds of DLBCL patients could be cured with standard frontline therapy ( 2 , 3 ).…”

Section: Introductionmentioning

confidence: 99%

“…Diffuse large B cell lymphoma (DLBCL) is the most common subtype of NHL ( 2 ). Approximately two thirds of DLBCL patients could be cured with standard frontline therapy ( 2 , 3 ). The standard therapy for relapsed or refractory (r/r) DLBCL patients was salvage chemotherapy, followed by autologous stem cell transplant (ASCT) ( 4 , 5 ).…”

Section: Introductionmentioning

confidence: 99%

A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma

Ying

He²,

Jin³

et al. 2022

Chinese Journal of Cancer Research

Self Cite

View full text Add to dashboard Cite

Objective Previous studies reported that 4-1BB-based CD19 chimeric antigen receptor (CAR)-T cells were more beneficial for the clinical outcomes than CD28-based CAR-T cells, especially the lower incidence rate of severe adverse events. However, the median progression-free survival (mPFS) of 4-1BB-based product Kymriah was shorter than that of CD28-based Yescarta (2.9 months vs. 5.9 months), suggesting that Kymriah was limited in the long-term efficacy. Thus, a safe and durable 4-1BB-based CD19 CAR-T needs to be developed. Methods We designed a CD19-targeted CAR-T (named as IM19) which consisted of an FMC63 scFv, 4-1BB and CD3ζ intracellular domain and was manufactured into a memory T-enriched formulation. A phase I/II clinical trial was launched to evaluate the clinical outcomes of IM19 in relapsed or refractory (r/r) B cell non-Hodgkin lymphoma (B-NHL). Dose-escalation investigation (at a dose of 5×10 5 /kg, 1×10 6 /kg and 3×10 6 /kg) was performed in 22 r/r B-NHL patients. All patients received a single infusion of IM19 after 3-day conditional regimen. Results At month 3, the overall response rate (ORR) was 59.1%, the complete response rate (CRR) was 50.0%. The mPFS was 6 months and the 1-year overall survival rate was 77.8%. Cytokine release syndrome (CRS) occurred in 13 patients (59.1%), with 54.5% of grade 1−2 CRS. Only one patient (4.5%) experienced grade 3 CRS and grade 3 neurotoxicity. Conclusions These results demonstrated the safety and durable efficacy of a 4-1BB-based CD19 CAR-T, IM19, which is promising for further development and clinical investigation.

show abstract

Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021 (English version)

Cited by 38 publications

References 45 publications

Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma

Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma

Identification of 14 Differentially-Expressed Metabolism-Related Genes as Potential Targets of Gastric Cancer by Integrated Proteomics and Transcriptomics

A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma

Contact Info

Product

Resources

About